最新临床试验：联合化疗、贝伐单抗和/或阿替唑单抗治疗DNA错配修复转移性结直肠癌

这是经美国国家癌症研究所批准的一项多中心临床三期随机对照试验，目的是研究联合化疗、贝伐单抗和/或阿替唑单抗治疗脱氧核糖核酸（DNA）错配缺陷患者如何有效修复扩散到身体其他部位的结直肠癌。用于化疗的药物，如氟尿嘧啶、奥沙利铂和白血球蛋白钙，以不同的方式阻止肿瘤细胞的生长，要么杀死肿瘤细胞，要么阻止肿瘤细胞分裂，要么阻止肿瘤细胞扩散。单克隆抗体的免疫治疗，如贝伐单抗和阿替唑单抗，可能有助于人体免疫系统攻击癌症，并可能干扰肿瘤细胞生长和扩散的能力。联合化疗、贝伐单抗和阿替唑单抗治疗结直肠癌可能效果更好。

该临床试验在全美352家医院进行开展。

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and / or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab and atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 352 locations